ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

mocertatug rezetecan

Also written as “Mocertatug rezetecan”, “HS-20089” and “Mocertatug rezetecan (Mo-Rez)”.

In GlaxoSmithKline’s pipeline, ADC targeting B7-H4. Its studies are mostly in Ovarian Neoplasms · Endometrial Neoplasms · Neoplasms, led by 2 companies.

Drug pageMocertatug rezetecan: every studyAll 12 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Dec 12, 202511 company-led studies, 11 open or runningLicense: Hansoh → GSK, Oct 2023Next primary completion: Mar 7, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
GlaxoSmithKlineits history only66 open or runningphase 3since Dec 12, 2025May 21, 2024Sep 22, 2027phase 1 · NCT06431594
Hansoh Pharmaceutical Group55 open or runningphase 3since Feb 25, 2025Oct 29, 2021Mar 7, 2027phase 3 · NCT06855069
  • Named in GlaxoSmithKline’s own pipeline as mocertatug rezetecan GSK5733584, phase 3, as of Sep 30, 2026 (source).
  • Named in Hansoh Pharmaceutical Group’s own pipeline as HS-20089 (B7-H4 ADC), phase 3, as of Aug 26, 2026 (source).

How these companies relate

From the companies’ own releases and filings, each linked; the registry does not say.

  • LicenseGSK licensed it from Hansoh, for everywhere outside mainland China, Hong Kong, Macau and Taiwan.Announced Oct 20, 2023 · Source: GSK, Oct 20, 2023

History and studies of Hansoh Pharmaceutical Group only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). A diamond marks a license, acquisition or co-development, from the companies’ own releases and filings. An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Oct 29, 2021First study: phase 1 study in Advanced Solid TumorFirst studyNCT05263479 · 177 planned · China
  2. Aug 16, 2023Phase 2 study in Ovarian NeoplasmsNCT06014190 · 460 planned · China
  3. Oct 20, 2023GSK licensed it from HansohLicenseEverywhere outside mainland China, Hong Kong, Macau and Taiwan · announced · GSK
  4. Jan 7, 2025Phase 1 study in Ovarian NeoplasmsNCT06769425 · 157 planned · China
  5. Feb 25, 2025Phase 3 study in Ovarian NeoplasmsNCT06855069 · 468 planned · China
  6. Jul 10, 2025Named mocertatug rezetecanINNProposed as its International Nonproprietary Name in WHO's List 133 · before, HS-20089
  7. Sep 2, 2026Phase 3 study in Platinum-sensitive Recurrent Ovarian CancerNCT07821606 · 460 planned · China

Ahead

  1. Mar 7, 2027Primary completion: phase 3 study in Ovarian NeoplasmsNCT06855069
  2. Dec 30, 2029Primary completion: phase 3 study in Platinum-sensitive Recurrent Ovarian CancerNCT07821606

TargetBeta

“ADC targeting B7-H4”the company's pipeline, read by Claude · source
“B7-H4 ADC”the company's pipeline, read by Claude · source
“An antibody-drug conjugate (ADC) composed of mocertatug, a humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against B7-H4 (V-set domain-containing T-cell activation inhibitor 1; VTCN1; B7x; B7S1) ”NCIt, by rule

Other programs on VTCN1

ProgramCompanyFurthest phaseStudies
Anti-B7-H4 Antibody Drug Conjugate BG-C9074ruleBeOne Medicinesphase 32
puxitatug samrotecanAstraZenecaphase 32
Anti-B7-H4/Anti-4-1BB Bispecific Antibody ABL103ruleabl-bio-incphase 22
Anti-B7-H4/MMAE ADC LNCB74ruleligachem-biosciences-incphase 11

Studies

All 5 Hansoh Pharmaceutical Group leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07821606Platinum-sensitive Recurrent Ovarian Cancer · China3Not yet recruitingDec 30, 2029460
NCT06855069Ovarian Neoplasms · China3RecruitingMar 7, 2027468
NCT06769425Ovarian Neoplasms · China1RecruitingMay 7, 2026157
NCT06014190Ovarian Neoplasms · China2RecruitingDec 31, 2025460
NCT05263479Advanced Solid Tumor · China1RecruitingDec 31, 2024177

How it is read

Names in the registry

  • “Mocertatug rezetecan”, 5 entries
  • “HS-20089”, 2 entries
  • “Mocertatug rezetecan (Mo-Rez)”, 1 entry
  • “HS-20089+Bevacizumab”, 1 entry
  • “HS-10502 + HS-20089”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.